Table 1.

Characteristics of the included studies.

Study name	Publication year	Country	No. of patients (Intervention /Comparator)	DDP-IV inhibitors	Other OADs	Therapy type	Study design	Follow-up period (weeks)	Timing of MAGE measurements
Kim HS et al.13	2013	Republic of Korea	16/17	Sitagliptin	Glimepiride	Add-on	Parallel	4	For 3 successive days at baseline and at the end of follow-up
Xiao et al.14	2016	China	23/18	Sitagliptin	Glimepiride	Combination	Parallel	24	For 72 hours, at baseline, 4, 8, 12, and 24- weeks
Kim NH et al.9	2017	Republic of Korea	14/11	Vildagliptin	Pioglitazone	Add-on	Parallel	16	For 3 consecutive days at baseline and at the end of follow-up
Park KS et al.15	2017	Republic of Korea	16/16	Vildagliptin	Glimepiride	Add-on	Crossover	12	For 3 consecutive day measurements, at baseline and at the end of follow-up
Kim G et al.16	2017	Republic of Korea	17/17	Vildagliptin	Glimepiride	Add-on	Parallel	12	For 3 consecutive day measurements, at baseline and at the end of follow-up
Park SE et al.10	2017	Republic of Korea	24a, 21b/17	Gemigliptin Sitagliptin	Glimepiride	Combination	Parallel	12	For 3 consecutive day measurements at baseline and at the end of follow-up
Suzuki et al.17	2018	Japan	26/26	Sitagliptin	Glibenclamide	Mono	Parallel	2	For 3 consecutive days at baseline and at the end of follow-up

Values are presented as mean ± SD, ^aGemigliptin + Metformin group, ^bSitagliptin + Metformin group.